Wei, AH, Reyner, JE, Garciaz, S, Aldoss, I, Piérola, A, Allred, A, Dominguez, JMA, Barreyro, L, Bories, P, Daskalakis, N, Porta, MGD, Döhner, H, D'Souza, A, Dugan, J, Fathi, A, Fedele, P, Ferrante, L, Kobos, R, Gaj, S, Diaz, AG, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jabbour, E, Trancucci, D, Bamidele, T, Jentzsch, M, Kantarjian, H, Konopleva, M, Krönke, J, Hütter-Krönke, ML, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Morillo, D, O'Nions, J, Packman, K, Papayannidis, C, Récher, C, Roellig, C, Salamero, O, Nagarajahastri, P, Sauer, T, Searle, E, Tovar, N, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Platzbecker, U. Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax plus Azacitidine (VEN plus AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/ Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Fernandez, RA, Arroyo, A, Cedena, MT, Rosiñol, L, De la Rubia, J, Miqueleiz, S, González-Calle, V, de Arriba, F, Casado-Montero, F, Hernandez, MT, Mas, M, Fernandez-Abellan, P, Rodriguez-Otero, P, Calle, C, Abella, E, Ribas, P, Alegre, A, Bergua, JM, Ocio, E, De la Cruz, J, Mateos, MV, San-Miguel, J, Bladé, J, Lahuerta, JJ, Martinez-Lopez, J. Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Follow-Up. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Gokul-Nath, R, Collins, C, Valverde, L, Lleixa, C, Verdu-Diaz, J, Di Lorenzo, A, Llarch, P, Querol, L, Marini-Bettolo, C, Rojas-Garcia, R, Diaz-Manera, J. Denervated human muscle fibers promote reinnervation via neurotrophic factor release in SMA and ALS. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105462. PMID:. IF:2.800(Q2/5D).

Olivella-Cirici, M, Vilagut, G, Sánchez-Ledesma, E, Serral, G, Cortés-Albaladejo, M, Cejas, PM, Pasarín, M, Alonso, J, Pérez, G. Gender and socioeconomic inequalities in adolescent mental well-being in Barcelona: a repeated cross-sectional study. Journal Of Public Health-Heidelberg. 2025; DOI:10.1007/s10389-025-02573-3. PMID:. IF:(Q/D).

Velasco, JIF, Jorge, FR, Monreal, E, Gracia, J, Díaz, EF, Meca-Lallana, V, Villarrubia, N, de la Maza, SS, Cortegana, EMP, Quiroga-Varela, A, Ramio-Torrentá, L, Martínez-Yélamos, S, Vila, LB, Real, AML, Romero, AR, Canelo, LB, Nicolas, SD, Eguia, P, Espiño, M, Garcia, JLC, Hernandez, FJB, González, JLV, Meca-Lallana, JE, Martos, PG, Gines, MLM, García-Dominguez, JM, Moreno, I, Sainz, R, Mañe, A, Rodriguez, ABC, Pinedo, FC, Labiano, A, Ayuso, L, Abreu, R, Hernández, MA, Rodríguez, MR, Martín-Aguilar, L, González, AH, Rojas, FJV, Cabredo, LF, Sanchez-Seco, VG, Muñoz, JS, Polo, LF, Castañon, IG, Moreno, SMG, Masjuan, J, Costa-Frossard, L, Guimerans, LMV. NfL and GFAP treatment-response serum biomarkers are influenced by elapsed time from MS onset to ocrelizumab initiation. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).

Olivé-Cirera, G, Falcioni, L, Fetta, A, Perez, EGF, Verdaguer, MG, Martinez, E, Sabaté, L, Saiz, A, Dalmau, J, Armangue, T. ADEM and other common radiological patterns shared in children with MOG-IgG and antibody-negative autoimmune encephalitis. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).